Showing 5441-5450 of 6661 results for "".
- Differin Celebrates Retinoid Awareness Week with Educational Initiativeshttps://practicaldermatology.com/news/differin-celebrates-retinoid-awareness-week-with-educational-initiatives/2460710/Following the FDA approval of Differin Gel to be sold over the-counter in 2016, Galderma embarked on a journey to educate consumers about retinoids like adapalene. In 2017, Differin launched its first ever Retinoid Education Week to continue to drive awareness. Now in its fourth year, D
- Baricitinib Performs Well in Phase 3 AA Trialhttps://practicaldermatology.com/news/baricitinib-performs-well-in-phase-3-aa-trial/2460709/Eli Lilly and Company and Incyte’s Baricitinib is the first JAK inhibitor to demonstrate hair regrowth in a Phase 3 alopecia areata (AA) trial. Patients with severe alopecia areata who took baricitinib 2-mg or 4-mg once daily showed a statistically significant improvemen
- Robert Moccia Takes the Helm at STRATA Skin Scienceshttps://practicaldermatology.com/news/robert-moccia-takes-the-helm-at-strata-skin-sciences/2460705/Robert (Bob) Moccia is the new President and Chief Executive Officer and a member of the board of STRATA Skin Sciences, Inc. He replaces Dolev Rafaeli, PhD, who stepped down last month. “I am confident that STRATA has the technology
- Project IMPACT from VisualDX Aims to Reduce Disparities in Medicinehttps://practicaldermatology.com/news/project-impact-from-visualdx-aims-reduce-disparities-in-medicine/2460704/VisualDX is launching Project IMPACT (Improving Medicine’s Power to Address Care and Treatment), a global effort to reduce disparities in medicine and highlight ways to bridge gaps of knowledge and improve healthcare outcomes for patients of color. Inaugural members include thought leaders
- Galderma and Aklief Unveil "Me Being Me" Campaign, Survey Results on Acne Zoom Burdenhttps://practicaldermatology.com/news/galderma-and-aklief-unveil-me-being-me-campaign-survey-results-on-acne-zoom-burden/2460703/Galderma Laboratories, L.P. and Aklief (trifarotene) Cream, 0.005% are launching Me Being Me, a new consumer campaign that was crafted in response to today’s increasingly digital-focused world. The campaign is designed to inspire those living with acne to feel confident
- ASDSA, Northwestern University Introduce Cutaneous Procedures Adverse Events Reporting (CAPER) Systemhttps://practicaldermatology.com/news/asds-northwestern-university-introduce-cutaneous-procedures-adverse-events-reporting-caper-system/2460701/The American Society for Dermatologic Surgery Association (ASDSA) and the Northwestern University Department of Dermatology are launching the Cutaneous Procedures Adverse Events Reporting (CAPER) system. This voluntary reporting system gathers patients’ adverse events (AEs) encoun
- AbbVie, Evolus Agree to Settlementhttps://practicaldermatology.com/news/abbvie-evolus-agree-to-settlement/2460697/AbbVie, Evolus, and Medytox have agreed to a new settlement to fully resolve all outstanding litigation, including the US International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case filed by Medytox against Evolus will be
- Industry Responds to COVID-19: NoSweathttps://practicaldermatology.com/news/industry-responds-to-covid-19-nosweat/2460695/Recognizing that any physical activity coupled with wearing a face shield can produce sweat that can get in the eyes and fog-up shields, NoSweat has created the first disposable performance liners specifically for face shields that absorb sweat while preventing fogging, odors, stains, and even ac
- Industry Responds to COVID-19: Janssen Pharmaceutical Companieshttps://practicaldermatology.com/news/industry-responds-to-covid-19-nosweat-janssen-pharmaceutical-companies/2460694/In response to the COVID-19 pandemic, Janssen Pharmaceutical Companies of Johnson & Johnson, “has been collaborating with regulators, healthcare organizations, institutions and communities worldwide to help ensure our research platforms, existi
- Dermavant: Promising Interim Analysis from Third Phase 3 Trial for Tapinarof in Psoriasishttps://practicaldermatology.com/news/dermavant-promising-interim-analysis-from-third-phase-3-trial-for-tapinarof-in-psoriasis/2460693/Positive results from a planned interim analysis of PSOARING 3, Dermavant Sciences’ long-term, open-label safety study, show that approximately 40 percent of subjects treated with investigational tapinarof cream, 1% achieved complete disease clearance (PGA score = 0). Treatment was well tol